Randomized Study for Patients With Follicular Lymphoma Needing Treatment

Status Completed

Clinical Trial Summary

2 parallel studies.

- For young patients (18-60 years): randomization between CHVP + interferon for 18 months and 4 CHOP followed by autotransplant after TBI

- For elderly patients (>60 years): randomization between CHVP + interferon for 18 months and fludarabine 5 days every months for 6 months

Clinical Trial Description

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00140569
Study type	Interventional
Source	Lymphoma Study Association
Contact
Status	Completed
Phase	Phase 3
Start date	January 1994
Completion date	January 2004

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01804686` - A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3
Completed	`NCT00001512` - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines	Phase 1
Recruiting	`NCT03676504` - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	Phase 1/Phase 2
Active, not recruiting	`NCT03245021` - Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A	Phase 1
Active, not recruiting	`NCT03078855` - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma	Phase 3
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Active, not recruiting	`NCT04082936` - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT02213263` - A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)	Phase 3
Completed	`NCT01691898` - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)	Phase 1/Phase 2
Terminated	`NCT03585725` - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma	Early Phase 1
Terminated	`NCT00772668` - Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL	N/A
Recruiting	`NCT02892695` - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	Phase 1/Phase 2
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Terminated	`NCT02204982` - Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma	Phase 3
Terminated	`NCT00850499` - Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab	Phase 2
Completed	`NCT02536664` - Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
Terminated	`NCT00475332` - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar	Phase 2
Terminated	`NCT00136591` - A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma	Phase 2
Not yet recruiting	`NCT06068881` - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation	Phase 2
Completed	`NCT04034056` - Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)